Table 1.
Baseline characteristics of the study population
| Variables | Outcome | P-value | |
|---|---|---|---|
| Present (n = 47) | Absent (n = 281) | ||
| Risk factors | |||
| Age (years) | 59.2 ± 9.4 | 59.4 ± 9.3 | 0.891 |
| Male gender | 30 (63.8) | 210 (74.7) | 0.154 |
| BMI (kg/m2) | 25.9 ± 3.2 | 25.4 ± 3.0 | 0.067 |
| Current smoking | 21 (44.7) | 160 (56.9) | 0.153 |
| Hypertension | 36 (76.6) | 226 (80.4) | 0.557 |
| Hyperlipidemia | 95 (80.5) | 77 (77.8) | 0.557 |
| PVD | 0 (0.0) | 6 (2.1) | 0.599 |
| Prior Stroke | 1 (2.1) | 12 (4.3) | 0.702 |
| Family history of CAD | 3 (6.4) | 32 (11.4) | 0.444 |
| LV-EF (%) | 61.7 ± 9.5 | 62.1 ± 8.1 | 0.805 |
| Laboratory test | |||
| hs-CRP (mg/L) | 6.8 ± 1.7 | 6.0 ± 1.4 | 0.805 |
| Neutrophil Count (109/L) | 3.9 ± 1.0 | 3.8 ± 1.2 | 0.797 |
| Fibrinogen (g/L) | 138.9 ± 16.6 | 137.2 ± 14.6 | 0.095 |
| Hemoglobin A1C (g/L) | 7.3 ± 1.5 | 6.8 ± 1.4 | 0.016 |
| Creatinine (umol/L) | 77.3 ± 15.9 | 76.2 ± 15.5 | 0.654 |
| NT-pro-BNP (fmol/mL) | 777.9 ± 736.0 | 731.8 ± 560.1 | 0.619 |
| Lipid profile | |||
| Remnant Cholestero (mmol/L) | 0.6 ± 0.6 | 0.6 ± 0.4 | 0.390 |
| Triglycerides (mmol/L) | 1.9 ± 0.8 | 1.7 ± 0.9 | 0.072 |
| Total Cholesterol (mmol/L) | 4.2 ± 1.3 | 3.9 ± 0.9 | 0.170 |
| LDL-C (mmol/L) | 2.5 ± 1.0 | 2.3 ± 0.8 | 0.208 |
| HDL-C (mmol/L) | 1.1 ± 0.3 | 1.1 ± 0.3 | 0.981 |
| Lipoprotein (a) (mg/L) | 272.3 ± 286.1 | 240.1 ± 237.4 | 0.405 |
| Apoprotein A-1 (g/L) | 1.5 ± 0.3 | 1.4 ± 0.3 | 0.386 |
| Apoprotein B (g/L) | 1.1 ± 0.3 | 1.0 ± 0.3 | 0.048 |
| Gensini scores (points) | 45.1 ± 41.8 | 32.0 ± 35.2 | 0.022 |
| DES Implantation | 31 (73.8) | 158 (68.7) | 0.825 |
| Medicine treatment | |||
| Aspirin | 46 (97.9) | 274 (97.5) | 1.000 |
| Clopidogrel | 45 (95.7) | 269 (95.7) | 1.000 |
| Statin | 47 (100.0) | 272 (96.8) | 0.368 |
| Beta-blocker | 42 (89.4) | 229 (81.5) | 0.218 |
| ACE-I/ARB | 30 (63.8) | 213 (75.8) | 0.105 |
BMI body mass index, PVD peripheral vascular disease, CAD coronary artery disease, hs-CRP high sensitivity C-reactive protein, NT-pro-BNP N-terminal pro-Brain natriuretic peptide, LV-FE left ventricular ejection fraction, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, DES drug eluting stent, ACE-I angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker